Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting validated biological pathways to address unmet medical needs in oncology and other indications. The company's lead program, ELVN-001, is a selective ATP-competitive tyrosine kinase inhibitor designed to treat chronic myeloid leukemia in patients with resistance to existing therapies or intolerance to their side effects. Enliven generates no commercial revenue and monetizes its pipeline through clinical development advancement, regulatory approval, and potential strategic partnerships or licensing agreements; the company outsources manufacturing and operates with an experienced team drawing from major pharmaceutical organizations.